Collaborations & Alliances

Y-Biologics, Pierre Fabre Enter Immuno-oncology Alliance

Aims to develop and commercialize a family of human antibodies to inhibit the growth of tumor cells.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Y-Biologics, a South Korean biotech, and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights to Pierre Fabre to develop and commercialize a family of human antibodies generated through the phage display human antibody Ymax-ABL library owned by Y-Biologics.   These antibodies have been functionally validated by Pierre Fabre R&D teams for their specific properties on a pivotal immuno-oncology target acting on the tumoral micr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters